Adding ribociclib, a CDK*4/6 inhibitor, to NSAI** and goserelin improves progression-free survival (PFS) in premenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC), according to the MONALEESA-7*** study presented at ESMO Asia 2018.
Treatment with the tyrosine kinase inhibitor cabozantinib led to improved tumour response, in terms of target lesion regression, alpha-fetoprotein (AFP) response, and time to disease progression compared with placebo in patients with advanced hepatocellular carcinoma (HCC) who had prior treatment with sorafenib, according to the CELESTIAL* trial presented at ESMO Asia 2018.
The addition of atezolizumab to standard of care (SOC) carboplatin and etoposide appears to improve overall survival (OS) and progression-free survival (PFS) in patients with extensive stage small cell lung cancer (ES-SCLC), setting in place a potential new SOC, according to the IMpower133* trial findings.
Stereotactic body radiotherapy (SBRT) is associated with significantly lower rates of acute gastrointestinal (GI) and genitourinary (GU) toxicities compared with conventional fractionated intensity-modulated radiotherapy (CF-IMRT) in Asian patients with early-stage localized prostate cancer.
Ceritinib is a cost-effective first-line treatment option for patients with ALK-positive advanced non-small-cell lung cancer (NSCLC) in Hong Kong compared with crizotinib, according to results of a study reported at the European Society for Medical Oncology (ESMO) Asia 2018 Congress.
The addition of the immune checkpoint inhibitor atezolizumab to standard-of-care (SoC) consisting of bevacizumab and chemotherapy in the first-line setting prolonged progression-free survival (PFS) and overall survival (OS) in individuals with non-squamous non-small-cell lung cancer (NSCLC) who were positive for EGFR* mutations, according to the IMpower150** trial presented at ESMO Asia 2018.
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
New drug applications approved by US FDA as of 16 - 30 November 2018
which includes New Molecular Entities (NMEs) and new biologics. It does
not include Tentative Approvals. Supplemental approvals may have
occurred since the original approval date.
Use of regional anaesthesia-analgesia using paravertebral blocks and the anaesthetic propofol does not lead to a lower risk of breast cancer recurrence after potentially curative surgery as compared with general anaesthesia with the volatile anaesthetic sevoflurane and opioid analgesia, according to a study.